Search

Displaying results 6711 - 6720 of 7674 in total
  1. Drug

    Inakalant

    go.drugbank.com/drugs/DB20424
    Investigational

    Inakalant has a monoisotopic molecular weight of 446.25 Da.

  2. Drug

    Alteminostat

    go.drugbank.com/drugs/DB19620
    Investigational

    Alteminostat has a monoisotopic molecular weight of 492.28 Da.

  3. Drug

    Nalorphine

    go.drugbank.com/drugs/DB11490
    ExperimentalVet approved

    It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics.

  4. Drug

    Gemilukast

    go.drugbank.com/drugs/DB19882
    Investigational

    Gemilukast has a monoisotopic molecular weight of 601.26 Da.

  5. Drug

    Idetrexed

    go.drugbank.com/drugs/DB21469
    Investigational

    Idetrexed has a monoisotopic molecular weight of 647.22 Da.

  6. Drug

    IL-2 pDNA

    go.drugbank.com/drugs/DB05935
    Experimental

    Vical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma

  7. Drug

    HMI-203

    go.drugbank.com/drugs/DB18520
    Investigational

    HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc.

  8. Drug

    RR001

    go.drugbank.com/drugs/DB17369
    Investigational

    RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand

  9. Drug

    Inetetamab

    go.drugbank.com/drugs/DB17457
    Investigational

    It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

  10. Drug

    Oregovomab

    go.drugbank.com/drugs/DB04964
    Investigational

    Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.